This inventor holds 19 USPTO granted patents and 3 published patent applications and 4 EPO patents, primarily in Enzyme Variants. Top assignees: Novozymes A/s, The Procter Gamble Company, Novo Nordisk A/s. Active years: 1999-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Frederiksberg, DK (1999 - 2001)
- Virum, DK (2011 - 2024)
Company Filing History:
14 out of 1,427 
3 out of 17,173 
2 out of 1,804 
Years Active: 1999-2025
Areas of Expertise:
Title: Mads E Bjoernvad: Innovator in Alpha-Amylase Variants
Introduction
Mads E Bjoernvad is a prominent inventor based in Frederiksberg, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of alpha-amylase variants. With a total of 19 patents to his name, Bjoernvad's work has had a substantial impact on various industrial applications.
Latest Patents
Among his latest patents, Bjoernvad has developed variants of a parent alpha-amylase. This invention relates to polynucleotides encoding these variants, as well as nucleic acid constructs, vectors, and host cells that incorporate the polynucleotides. Additionally, he has created variants and compositions that exhibit high stability in the presence of chelating agents. This invention focuses on alpha-amylase variants that demonstrate improved stability compared to their parent enzyme, along with methods for producing and utilizing these variants.
Career Highlights
Throughout his career, Mads E Bjoernvad has worked with notable companies such as Novozymes A/S and The Procter & Gamble Company. His expertise in enzyme technology has positioned him as a key player in the biotechnology sector.
Collaborations
Bjoernvad has collaborated with esteemed colleagues, including Allan Svendsen and Svend Gunnar Kaasgaard. These partnerships have further enhanced his research and development efforts in the field of enzyme variants.
Conclusion
Mads E Bjoernvad's innovative work in alpha-amylase variants showcases his dedication to advancing biotechnology. His numerous patents and collaborations reflect his significant contributions to the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile